Ultragenyx Pharmaceutical Inc.
RARE
$21.34
-$0.37-1.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -575.00M | -579.65M | -532.75M | -549.40M | -569.00M |
| Total Depreciation and Amortization | 35.00M | 35.75M | 35.90M | 36.15M | 36.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 97.00M | 99.16M | 100.58M | 110.12M | 105.00M |
| Change in Net Operating Assets | -23.00M | -755.00K | -24.79M | 13.39M | 14.00M |
| Cash from Operations | -466.00M | -445.49M | -421.06M | -389.75M | -414.00M |
| Capital Expenditure | -6.00M | -5.23M | -5.56M | -5.11M | -7.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 242.00M | 415.98M | 23.63M | 12.57M | -11.00M |
| Cash from Investing | 236.00M | 410.75M | 18.07M | 7.46M | -18.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 86.00M | 86.75M | 90.93M | 392.16M | 392.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 392.00M | 0.00 | 7.00M | 7.06M | 7.00M |
| Cash from Financing | 478.00M | 86.75M | 97.93M | 399.22M | 399.00M |
| Foreign Exchange rate Adjustments | 4.00M | 2.71M | 3.69M | 127.00K | -2.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 252.00M | 54.73M | -301.38M | 17.05M | -35.00M |